NCT04497142View on ClinicalTrials.gov

Effect of Perampanel on Peritumoral Hyperexcitability in HGG

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

November 5, 2020

Primary Completion Date

May 16, 2023

Study Completion Date

May 16, 2023

Conditions
Glioma, MalignantSurgerySeizures
Interventions
DRUG

Perampanel

Tablet taken orally 1x daily.

DRUG

Standard of Care

Predetermined standard of care drug and dosing

Trial Locations (1)

02215

Brigham and Women's Hospital, Boston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Eisai Inc.

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER

NCT04497142 - Effect of Perampanel on Peritumoral Hyperexcitability in HGG | Biotech Hunter | Biotech Hunter